Abstract:Ednan K Bajwa, 1 Dawn Cislak, 1 Amit Kumar, 1 Dan Li, 1 Eric J Messina, 1 Tom Reynders, 2 Jean-François Denef, 2 Vasile Corcea, 3 Ketan P Buch, 4 Eseng Lai, 1 S Aubrey Stoch 1 1 MRL, Merck & Co., Inc., Rahway, NJ, USA; 2 Translational Medicine, MSD Belgium, Brussels, Belgium; 3 PMSI Republican Clinical Hospital "T. Mosneaga", ARENSIA EM Unit, Chisinau, Republic of Moldova; 4 Department of Internal Medicine, Pulmonary and Critical Care Medicine, Lexington VA Healthcare, Lexington, KY, USA Correspondence: Ednan K Bajwa, Translational Medicine, Merck Research Laboratories Massachusetts LLC, 33 Avenue Louis Pasteur, MAILSTOP BMB-3-420, Boston, MA, 02115-5727, USA, Tel +1 617 992-3470, Email Purpose: This phase 1 study (NCT04370873) evaluated safety and pharmacokinetics/pharmacodynamics (PK/PD) of MK-5475 in participants with pulmonary hypertension associated with COPD (PH-COPD). Methods: Eligible participants were 40– 80 years old with COPD (FEV 1 /FVC < 0.7; FEV 1 > 30% predicted) and PH (mean pulmonary arterial pressure ≥ 25 mmHg). Participants were randomized 2:1 to MK-5475 or placebo via dry-powder inhaler once daily for 7 days in Part 1 (360 μg) or 28 days in Part 2 (380 μg). Safety was assessed by adverse events (AEs) and arterial blood oxygenation. Part-2 participants had pulmonary vascular resistance (PVR; primary PD endpoint) and pulmonary blood volume (PBV; secondary PD endpoint) measured at baseline and Day 28. A non-informative prior was used to calculate posterior probability (PP) that the between-group difference (MK-5475 – placebo) in mean percent reduction from baseline in PVR was less than − 15%. Results: Nine participants were randomized in Part 1, and 14 participants in Part 2. Median age of participants (86.4% male) was 68.5 years (41– 77 years); 95.5% had moderate-to-severe COPD. Incidences of AEs were comparable between MK-5475 and placebo: overall (5/14 [36%] versus 5/8 [63%]), drug-related (1/14 [7%] versus 2/8 [25%]), and serious (1/14 [7%] versus 1/8 [13%]). MK-5475 caused no meaningful changes in arterial blood oxygenation or PBV. MK-5475 versus placebo led to numerical improvements from baseline in PVR (− 21.2% [95% CI: − 35.4, − 7.0] versus − 5.4% [95% CI: − 83.7, 72.9]), with between-group difference in PVR less than − 15% and calculated PP of 51%. Conclusion: The favorable safety profile and numerical reductions in PVR observed support further clinical development of inhaled MK-5475 for PH-COPD treatment. Keywords: pulmonary hypertension, chronic obstructive pulmonary disease, MK-5475, soluble guanylate cyclase stimulator, dry powder inhaler, pulmonary vascular resistance Chronic obstructive pulmonary disease (COPD) is an often-debilitating lung disease that can be further complicated by pulmonary hypertension (PH). 1,2 PH associated with COPD (PH-COPD) leads to greater morbidity, mortality, and utilization of healthcare resources than does COPD associated with normal pulmonary pressures. 3 The mechanisms by which PH arises in the context of COPD are unclear, but the associated pulmonary vascular remodeling is like that seen with other PH manifestations, 3–9 such as pulmonary arterial hypertension (PAH), including thickening of the pulmonary arterial walls, obliteration of the vascular lumen, and elevation of mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR). PH-COPD (World Health Organization [WHO] Group 3 PH) lacks any approved therapeutic treatment. 10,11 Despite the pathophysiological similarities with PAH (WHO Group 1 PH), the vasodilators used for the treatment of PAH 12 have not consistently shown efficacy against PH-COPD. 5,13–16 Vasodilators like phosphodiesterase type-5 inhibitors (PDE5i) and the soluble guanylate cyclase (sGC) stimulator, riociguat, act on the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway to increase the production of cGMP, which potentiates tissue relaxation in vascular smooth muscle cells. 17 Although nonclinical data suggest that targeting the NO-cGMP pathway with PDE5i and sGC stimulators may positively affect PH-COPD in animals, 18,19 studies of PDE5i and riociguat in patients with PH-COPD have shown mixed results. 20,21 Another concern with coopting PAH treatment strategies for PH-COPD treatment is the potential for systemic side effects of vasodilation, particularly with combination therapy regimens. Systemic vasodilators may inhibit hypoxic pulmonary vasoconstriction in poorly ventilated regions of lung tissue in patients with PH-COPD, leading to a v -Abstract Truncated-

CHF6523 data suggest that the phosphoinositide 3-kinase delta isoform is not a suitable target for the management of COPD

Discovery of CHF-6523, an Inhaled Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease

Advances in the Discovery of Novel Inhaled PI3K Inhibitors for the Treatment of Asthma

Progression of the PI3K/Akt signaling pathway in chronic obstructive pulmonary disease

Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials

Impacts of anti-inflammatory phosphodiesterase inhibitors on a murine model of chronic pulmonary inflammation

Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD

A PI3Kγ Mimetic Peptide Triggers CFTR Gating, Bronchodilation, and Reduced Inflammation in Obstructive Airway Diseases

Potential for inhibition of checkpoint kinases 1/2 in pulmonary fibrosis and secondary pulmonary hypertension

Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis

Discovery of (S)-2-(1-(4-amino-3-(3-fluoro-4-methoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3h)-one (Ihmt-Pi3kδ-372) As a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease

Next generation of anti-inflammatory therapy for COPD?

CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder

Protein phosphatase 2A activators under investigation for smoking-related chronic obstructive pulmonary disease and related disorders

Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease

p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics

Unleashing the Power of IL-17: A Promising Frontier in Chronic Obstructive Pulmonary Disease (COPD) Treatment

The Importance of the Interleukin-8 Study in Chronic Obstructive Pulmonary Disease

Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis